Request Live Training

Cerianna (fluoroestradiol F 18) injection is the only imaging agent that detects whole-body ER+ lesions in recurrent or metastatic breast cancer patients that may inform clinical decisions.

GE HealthCare has designed peer-to-peer reader training programs in a variety of formats to help you accurately interpret Cerianna images.

We offer convenient on-demand and live virtual training to fit your learning style and schedule.

Register by using the form to request a training session. You will be contacted by our training team within 48 hours.

Looking for On-Demand Reader Training?

We offer convenient, on-demand training to fit your learning style and schedule. Register by clicking on the button below.

About Cerianna™

Cerianna PET reveals whole-body ER+ lesion status in patients with recurrent or metastatic breast cancer that may help guide clinical decisions.

INDICATIONS AND USAGE

CERIANNA is indicated for use with positron emission tomography (PET) imaging for the detection of estrogen receptor (ER)-positive lesions as an adjunct to biopsy in patients with recurrent or metastatic breast cancer.

LIMITATIONS OF USE

Tissue biopsy should be used to confirm recurrence of breast cancer and to verify ER status by pathology. CERIANNA is not useful for imaging other receptors, such as human epidermal growth factor receptor 2 (HER2) and the progesterone receptor (PR).

CONTRAINDICATIONS

None.

ADVERSE REACTIONS

In clinical trials evaluating the safety of CERIANNA in patients with breast cancer (n=1207), the following adverse reactions occurred at a rate < 1%: injection-site pain and dysgeusia.

To report SUSPECTED ADVERSE REACTIONS, contact Zionexa US Corp, a GE HealthCare Company at +1.800.654.0118 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

For full Prescribing Information, click here.

GE HealthCare | Privacy Policy | Terms of Use | Contact Us | Unsubscribe

500 W. Monroe Street | Chicago, IL 60661

© 2024 GE HealthCare

Cerianna is a trademark of GE HealthCare.

GE is a trademark of General Electric Company used under trademark license.

September 2023 | JB07297US